HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

被引：118
|
作者：
Kemp, Troy J. [1 ]
Hildesheim, Allan [2 ]
Safaeian, Mahboobeh [2 ]
Dauner, Joseph G. [1 ]
Pan, Yuanji [1 ]
Porras, Carolina [3 ]
Schiller, John T. [4 ]
Lowy, Douglas R. [4 ]
Herrero, Rolando [3 ]
Pinto, Ligia A. [1 ]
机构：
[1] NCI Frederick, HPV Immunol Lab, SAIC Frederick Inc, Frederick, MD 21702 USA
[2] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[3] Fdn INCIENSA, Proyecto Epidemiol Guanacaste, San Jose, Costa Rica
[4] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
VACCINE | 2011年 / 29卷 / 11期
基金：
美国国家卫生研究院;
关键词：
Human papillomavirus; Antibody; Vaccine; PARTICLE VACCINE; YOUNG-WOMEN; INFECTION; EFFICACY; IMMUNIZATION; RESPONSES; TYPE-18; HPV-18;
D O I：
10.1016/j.vaccine.2011.01.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Human papillomavirus (HPV) L1 VLP-based vaccines are protective against HPV vaccine-related types; however, the correlates of protection have not been defined. We observed that vaccination with Cervarix (TM) induced cross-neutralizing antibodies for HPV types for which evidence of vaccine efficacy has been demonstrated (HPV31/45) but not for other types (HPV52/58). In addition, HPV31/45 cross-neutralizing titers showed a significant increase with number of doses (HPV31, p < 0.001; HPV45, p < 0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine.(C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2011 / 2014
页数：4
相关论文
共 48 条
  • [1] Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice
    Chen, Xue
    Zhang, Ting
    Liu, Hongyang
    Hao, Yaru
    Liao, Guoyang
    Xu, Xuemei
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 2025 - 2033
  • [2] Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines
    Zhang, Ting
    Chen, Xue
    Liao, Guoyang
    Hu, Meili
    Xu, Jianqing
    Xu, Xuemei
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (12) : 3750 - 3758
  • [3] NHPV16VLP vaccine induces human antibodies that neutralize divergent variants of HPV16
    Pastrana, DV
    Vass, WC
    Lowy, DR
    Schiller, JT
    VIROLOGY, 2001, 279 (01) : 361 - 369
  • [4] Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types
    Szarewski, Anne
    EXPERT REVIEW OF VACCINES, 2012, 11 (06) : 645 - 657
  • [5] A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity
    Leng, Chih-Hsiang
    Liu, Shih-Jen
    Tsai, Jy-Ping
    Li, Yi-Shiuan
    Chen, Mei-Yu
    Liu, Hsueh-Hung
    Lien, Shu-Pei
    Yueh, Andrew
    Hsiao, Kuang-Nan
    Lai, Li-Wei
    Liu, Feng-Chuan
    Chong, Pele
    Chen, Hsin-Wei
    MICROBES AND INFECTION, 2009, 11 (02) : 288 - 295
  • [6] Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies
    Godi, Anna
    Bissett, Sara L.
    Miller, Elizabeth
    Beddows, Simon
    JOURNAL OF GENERAL VIROLOGY, 2017, 98 (07): : 1755 - 1761
  • [7] Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Kohli, Michele
    Lawrence, Donna
    Haig, Jennifer
    Anonychuk, Andrea
    Demarteau, Nadia
    BMC PUBLIC HEALTH, 2012, 12
  • [8] Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine
    Dauner, Joseph G.
    Pan, Yuanji
    Hildesheim, Allan
    Harro, Clayton
    Pinto, Ligia A.
    VACCINE, 2010, 28 (33) : 5407 - 5413
  • [9] VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1
    Bolhassani, Azam
    Shirbaghaee, Zeinab
    Agi, Elnaz
    Davoudi, Noushin
    PROTEIN EXPRESSION AND PURIFICATION, 2015, 116 : 7 - 11
  • [10] Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques
    Wang, Yan
    Liu, Yuying
    Liang, Shutian
    Yin, Fei
    Zhang, Haijiang
    Liu, Yongjiang
    PAPILLOMAVIRUS RESEARCH, 2020, 10
12345